DE3789413T2 - Lymphokin-ähnliche Peptide. - Google Patents

Lymphokin-ähnliche Peptide.

Info

Publication number
DE3789413T2
DE3789413T2 DE3789413T DE3789413T DE3789413T2 DE 3789413 T2 DE3789413 T2 DE 3789413T2 DE 3789413 T DE3789413 T DE 3789413T DE 3789413 T DE3789413 T DE 3789413T DE 3789413 T2 DE3789413 T2 DE 3789413T2
Authority
DE
Germany
Prior art keywords
lymphokine
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3789413T
Other languages
English (en)
Other versions
DE3789413D1 (de
Inventor
Karel Gerrit Dr Odink
Roger Dr Clerc
Nico Dr Cerletti
Josef Dr Brueggen
Lajos Dr Tarcsay
Clemens Prof Dr Sorg
Walter Wiesendanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868623850A external-priority patent/GB8623850D0/en
Priority claimed from GB868628358A external-priority patent/GB8628358D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of DE3789413D1 publication Critical patent/DE3789413D1/de
Publication of DE3789413T2 publication Critical patent/DE3789413T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
DE3789413T 1986-10-03 1987-09-28 Lymphokin-ähnliche Peptide. Expired - Fee Related DE3789413T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868623850A GB8623850D0 (en) 1986-10-03 1986-10-03 Lymphokine related peptide
GB868628358A GB8628358D0 (en) 1986-11-27 1986-11-27 Lymphokine related peptides

Publications (2)

Publication Number Publication Date
DE3789413D1 DE3789413D1 (de) 1994-04-28
DE3789413T2 true DE3789413T2 (de) 1994-07-28

Family

ID=26291377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3789413T Expired - Fee Related DE3789413T2 (de) 1986-10-03 1987-09-28 Lymphokin-ähnliche Peptide.

Country Status (11)

Country Link
US (2) US5350687A (de)
EP (1) EP0263072B1 (de)
JP (1) JPH09188698A (de)
AU (1) AU7930987A (de)
DE (1) DE3789413T2 (de)
DK (1) DK517787A (de)
ES (1) ES2052602T3 (de)
FI (1) FI874287A (de)
IE (1) IE61773B1 (de)
NO (1) NO874159L (de)
PT (1) PT85849B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750604B1 (fr) * 1996-07-02 2002-09-20 Oreal Heteromere liant l'acide arachidonique et son utilisation en cosmetique ou pharmacie
EP0463037A1 (de) * 1989-03-17 1992-01-02 Genetics Institute, Inc. Humanmakrophagen-migrationsinhibitionsfaktor
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
JP2747839B2 (ja) * 1989-08-14 1998-05-06 花王株式会社 モノクローナル抗体
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation
ATE228164T1 (de) * 1990-09-05 2002-12-15 Heart Res Inst Ltd Chemotaktische faktoren
CH685959A5 (de) * 1992-08-24 1995-11-15 Biomedicals Ag Diagnostische Testpackung zur Bestimmung von Proteinen.
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
JP2001509029A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトタンパク質
US6706683B1 (en) 1998-09-29 2004-03-16 Asahi Kasei Pharma Corporation Method for controlling the release of granules
JP4820003B2 (ja) * 1998-11-05 2011-11-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌の血清マーカーとしてのｓ１００タンパク質および自己抗体
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
AU2003212246A1 (en) * 2002-02-15 2003-09-04 Johannes Roth Method for diagnosis of inflammatory diseases using mrp8/mrp14
EP1519749B1 (de) * 2002-07-05 2009-04-08 Universite Laval Inhibitor des chemotaktischen faktors zur hemmung der entzündungsreaktionen
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) * 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
WO2004084928A1 (en) 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
CA2531506A1 (en) * 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
WO2005082008A2 (en) * 2004-02-25 2005-09-09 The United States Of America As Represented By The Department Ofveterans Affairs Methods for diagnosing and treating bladder cancer
SE0400886D0 (sv) * 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
EP1784216A4 (de) * 2004-07-13 2009-06-03 Univ Laval S100 proteinhemmer zur behandlung von leukämie
SG150497A1 (en) 2004-07-23 2009-03-30 Aspenbio Pharma Inc Methods and devices for diagnosis of appendicitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
CA2600175A1 (en) * 2005-03-24 2006-03-20 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
ES2574137T3 (es) * 2008-09-03 2016-06-15 Quantumdx Group Limited Estrategias y métodos de detección de ácidos nucleicos mediante biosensores
CN103562702A (zh) 2011-05-20 2014-02-05 独立行政法人理化学研究所 生物材料用透明化试剂、及其利用
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
US10626166B2 (en) * 2014-08-22 2020-04-21 Baxalta Incorporated Detection of CHO-MIF contaminations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230876C (de) *
US4322274A (en) * 1980-08-28 1982-03-30 Wilson Gregory B Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
GB2125047B (en) 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS6041697A (ja) * 1983-08-15 1985-03-05 Asahi Chem Ind Co Ltd 活性蛋白質誘導体の新規合成法
PH22337A (en) 1983-11-21 1988-08-12 Ciba Geigy Ag Synthesis of fibrinolytic agents by yeast
PT79519B (en) 1983-11-21 1986-12-11 Ciba Geigy Ag Process for preparing protease inhibitors based on egline compounds
JPH0672158B2 (ja) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines

Also Published As

Publication number Publication date
US5350687A (en) 1994-09-27
NO874159L (no) 1988-04-05
US5702920A (en) 1997-12-30
FI874287A (fi) 1988-04-04
ES2052602T3 (es) 1994-07-16
EP0263072A3 (en) 1990-01-10
DK517787D0 (da) 1987-10-02
AU7930987A (en) 1988-05-19
FI874287A0 (fi) 1987-09-30
EP0263072A2 (de) 1988-04-06
EP0263072B1 (de) 1994-03-23
IE61773B1 (en) 1994-11-30
DK517787A (da) 1988-04-04
JPH09188698A (ja) 1997-07-22
NO874159D0 (no) 1987-10-02
PT85849A (en) 1987-11-01
IE872645L (en) 1988-04-03
PT85849B (pt) 1990-07-31
DE3789413D1 (de) 1994-04-28

Similar Documents

Publication Publication Date Title
DE3789413T2 (de) Lymphokin-ähnliche Peptide.
ATE110743T1 (de) Antikoagulierende peptide.
DK97790A (da) Renin-inhiberende peptider
NO892294D0 (no) Polypeptidforbindelser.
NO881384D0 (no) Peptider.
NO885108D0 (no) Peptider.
DK197989A (da) Peptidanaloger
DK354487D0 (da) Oncogen-relaterede peptider
DK531986D0 (da) Peptider
FI851488A0 (fi) Peptider.
KR900700503A (ko) 펩티드
DE3685636T2 (de) Lysozymbetreffende peptide.
DE3780388D1 (de) Fsh-stimulierendes peptid.
NO872386D0 (no) Peptider.
DE3869939D1 (de) Biologisch wirksame peptide.
ATE103339T1 (de) Lymphokin-aehnliche peptide.
DE68914057T2 (de) Peptide.
NO883008D0 (no) Peptidforbindelser.
DE3774988D1 (de) Peptidderivate.
NO910981D0 (no) Peptidforbindelser.
DE69006311D1 (de) Antimetastatische peptide.
DK91686D0 (da) Peptider
DK91586D0 (da) Peptider
DK435086D0 (da) Peptider
DK434986D0 (da) Peptider

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8339 Ceased/non-payment of the annual fee